Mandate

Vinge has advised ABG Sundal Collier and Carnegie in connection with Permascand’s listing on Nasdaq First North Premier Growth Market

June 04, 2021

Vinge has advised ABG Sundal Collier and Carnegie in connection with Permascand’s listing on Nasdaq First North Premier Growth Market. Trading on Nasdaq First North Premier Growth Market commenced on 4 June 2021.

The price per share in the offering was SEK 34 per share, corresponding to a total value of approximately SEK 2,017 million for all outstanding shares in the Permascand following the completion of the offering. The Offering comprised 14,860,627 shares, corresponding to approximately 25.1 percent of the total number of shares in the company following the completion of the offering, of which 8,823,529 shares were newly issued shares and 6,037,098 shares were existing shares sold by Norvestor VI, L.P. and a few other shareholders

Permascand is an independent technology-driven manufacturer of electrochemical solutions based on proprietary catalytic coatings for cleantech applications. With a customer-centric focus, Permascand has supplied electrodes, electrochemical cells, and aftermarket services to a variety of sectors for the past 50 years.

Vinge’s team consisted of Dain Hård Nevonen, Linnéa Sellström and Eléonore Friberg.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025